| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0755 | Ast7062601 | Novel AKAP1/PKA modulator, inducing UCP1 expression and thermogenesis |
|
| DCC0756 | asterriquinone | Inhibitor of HIV-reverse transcriptase activity |
|
| DCC0757 | Asymmetric Dimethylarginine | Natural endogenous inhibitor of nitric oxide synthases (NOS), also inhibiting arginine transport and increasing oxygen free radicals, mitochondrial dysfunction and transforming growth factor beta (TGFβ) expression, exhibiting a strong association with car |
|
| DCC0758 | asyn-in-576755 | Novel inhibitor of αSyn fibrillization, blocking fibril growth and suppressing A53T αSyn neurotoxicity |
|
| DCC0759 | At-076 | The First Small-molecule Opioid Pan Antagonist with Nanomolar Affinity at Mu, Delta, Kappa and Nociceptin Opioid Receptors. |
|
| DCC0760 | At-089 | Novel NOP receptor-mu opioid receptor ligand |
|
| DCC0761 | At-1001 | Novel potent and selective partial agonist of human and rat α3β4 nicotinic cholinergic receptors |
|
| DCC0762 | At-1012 | High affinity, selective alpha3beta4 nAChR ligand |
|
| DCC0763 | At-121 | Novel dual μ-opioid and nociceptin receptor partial agonist (K i = 16.49 and 3.67 nM, respectively) |
|
| DCC0764 | At-265 | Nucleosidic antibiotic |
|
| DCC0765 | At-312 | Novel selective nociceptin receptor (NOP) agonist |
|
| DCC0766 | At7519m | Novel inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 with in vitro activity against lymphoid malignancies |
|
| DCC0767 | Atag2139 | Novel degrader of MTH1 fusion proteins for use within the aTAG system |
|
| DCC0768 | aTAG 4531 Featured | aTAG 4531 (CFT-4531) is a potent, selective, and onmechanism tool degrader of MTH1 with DC50 value of 0.28 nM and Ki value of 1.8 nM. degradation activity is due to the intricate formation of the ternary complex between the MTH1 aTAG, CRBN E3 ligase, and aTAG tool degrader . |
|
| DCC0769 | Atb-345 | Hydrogen sulfide-releasing cyclooxygenase inhibitor |
|
| DCC0770 | Atcaa-1 | Potent cytotoxic agent for both prostate cancer and melanoma |
|
| DCC0771 | Atd-3169 | Novel ROS generator, permeating mycobacteria to reliably enhance endogenous ROS including superoxide radical |
|
| DCC0772 | Atenolol Hydrochloride | Selective ß1 receptor antagonist |
|
| DCC0773 | Atiprimod Dimaleate | Potent JAK2 inhibitor |
|
| DCC0774 | Atl802 | Novel selective A2BR antagonist |
|
| DCC0775 | Atm-1001 | Novel inhibitor of the cancer-associated tropomyosin 3.1 (Tpm3.1), suppressing glucose-stimulated insulin secretion (GSIS) from the pancreatic islets |
|
| DCC0776 | a-tocopheryl 2,3,5-triiodobenzoate | Novel non-toxic contrast agent for micro-CT imaging |
|
| DCC0777 | Atp-alpha-ch2-gamma-thio | Novel potent inhibitor of nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) |
|
| DCC0778 | atqthb | Novel antitimor agent, exhibiting superior anti-proliferative activity, excellent chemo-sensitizing activity against pancreatic cancer in vitro and in combination with Gemcitabine |
|
| DCC0779 | Atromentin | Natural potent apoptosis inducer in U937 cells, inducing caspase-3 processing, PARP, and DNA fragmentation |
|
| DCC0780 | Atsp-3900 | Novel Potent Dual Inhibitor of MDM2 and MDMX (Ki =1 nM) |
|
| DCC0781 | Atsp-7041 | Novel potent and selective dual inhibitor of MDM2 (Ki = 0.9 nM) and MDMX (Ki = 7 nM) |
|
| DCC0782 | Atuveciclib | Novel potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor |
|
| DCC0783 | Atx-1905 | Novel Potent Autotaxin (ATX) Ligand |
|
| DCC0784 | Atx-in-31 | Novel selective Autotaxin (ATX) inhibitor |
|
